Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 2, 2025

Supplementary Figure 2 from Sustained Macrophage Reprogramming Is Required for CD8+ T cell–Dependent Long-Term Tumor Eradication

View Full Paper
Ask AI
Bookmark
Share

Authors

CJCarolina JardimMBMarta BicaMRMariana Reis-Sobreiro

Discussion

Loading...

Member takes

Overview

Research demonstrates the importance of macrophage reprogramming for long-term tumor eradication by CD8 T cells, implying enhanced immune response.

Key Points

  • Sustained macrophage reprogramming is critical for achieving long-term eradication of tumors.
  • CD8 T cells play a vital role in mediating the tumor eradication process through their immune response.
  • The study explores mechanisms behind macrophage and T cell interactions in tumor environments.
  • Findings highlight the potential for improved cancer therapies by targeting macrophage reprogramming.

Cite This Study

Jardim et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d0147https://doi.org/10.1158/2326-6066.29760920
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Data from Sustained Macrophage Reprogramming Is Required for CD8<sup>+</sup> T cell–Dependent Long-Term Tumor Eradication2025
  2. 2Supplementary Figure 14 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma2025
  3. 3Supplementary Figure 15 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma2025
  4. 4Supplementary Figure 13 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma2025
  5. 5Supplementary Figure 6 from CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool2024